The European Antitrust Agenda: Booking/Etraveli Ruling to Bring Blessing, ‘Flesh Wound’; Aramark Dispute Advances

Welcome to The European Antitrust Agenda, our weekly overview of European tech and competition law developments. Key stories we’re following this week include: • Long-awaited ruling on blocked Booking-Etraveli merger lands • Aramark pursues high-profile challenge in missed deadline case • What else is happening

Ligado Networks: Court Ruling Puts at Risk Company’s $39 Billion Lawsuit Against U.S. Government

A Federal Claims Court judge’s ruling this week will delay—and could even derail—Ligado Networks’ effort to seek $39 billion from the U.S. government for allegedly preventing the company from...

Sep 04, 2026 Read Now >

Financials Friday: How a Democratic President Could Boot Life Insurance Companies Out of the Federal Home Loan Bank System; New Republican Bill Targets CFPB Funding; Banks Get Into Stablecoin Business; Last Bastion of Private Listings Opposition Falls to Compass; New Jersey Kicks Kalshi Dispute to SCOTUS

Financials Friday is a weekly overview of financial news and analysis of the timing and priorities of key agencies including the Federal Reserve, OCC and FDIC. Key stories we’re following this week...

Sep 04, 2026 Read Now >

Google: Judge Voices Concern About Impact of AI Overviews on Publishers, But Penske, Chegg Still Face Standing Hurdles

As U.S. District Judge Amit Mehta decides whether to dismiss litigation targeting Google’s (GOOG) AI Overviews, the publisher plaintiffs may have reason for optimism after the judge expressed...

Sep 04, 2026 Read Now >

The European Antitrust Agenda: Booking/Etraveli Ruling to Bring Blessing, ‘Flesh Wound’; Aramark Dispute Advances

RELATED ARTICLES | Antitrust Policy

Ligado Networks: Court Ruling Puts at Risk Company’s $39 Billion Lawsuit Against U.S. Government

Google: Judge Voices Concern About Impact of AI Overviews on Publishers, But Penske, Chegg Still Face Standing Hurdles

FILTER BY

This article is currently locked and only available to subscribers. Request a trial to receive unlimited access to all articles.